Table 1 Model input parameters

Sn_C

Sensitivity of CMR

0.82

0.77-0.86

[17]

Sp_C

Specificity of CMR

0.86

0.82-0.89

[17]

Sn_S

Sensitivity of SPECT

0.67

0.60-0.72

[17]

Sp_S

Specificity of SPECT

0.83

0.79-0.86

[17]

Sn_A

Sensitivity of angiography

1.00

N/A

[19–21]

Sp_A

Specificity of angiography

1.00

N/A

[19–21]

R_C

Complication rate with CMR

0.0005

0.0001-0.001

[23]

R_S

Complication rate with SPECT

0.0005

0.0001-0.001

[20]

R_A

Complication rate with angiography

0.005

0.001-0.01

[28]

R_F

Complication rate for patients with CAD and false-negative test results*

0.25

0.15-0.30

[20, 21]

M_C

Mortality rate due to CMR

0.00005

0.00001-0.0001

[20, 24]

M_S

Mortality rate due to SPECT

0.00005

0.00001-0.0001

[20, 24]

M_A

Mortality rate due to angiography

0.00075

0.0001-0.0015

[28]

M_F

Mortality rate for patients with CAD and false-negative test results*

0.20

0.15-0.25

[19, 20]

NDx_C

Rate of non-diagnostic CMR

0.05

0.01-0.1

[17, 25]

NDx_S

Rate of non-diagnostic SPECT

0.05

0.01-0.1

[17, 25]

NDx_A

Rate of non-diagnostic angiography

0.00

N/A

[19–21]

C_C

Cost of CMR [in €]

703

527-879

[31, 34]

C_S

Cost of SPECT [in €]

504

378-630

[30, 33]

C_A

Cost of angiography [in €]

2,926

2,195-3,658

[29, 35]

C

Cost of a complication^# [in €]

14,478

10,859-18,098

[21, 36]

N_C

No. of patients having CMR

1.0

N/A

[21]

N_S

No. of patients having SPECT

1.0

N/A

[21]

N_A

No. of patients having angiography

varies

Equation 1a

[19–21]

NF_C

No. of false-negative CMR

varies

Equation 1a

[19–21]

NF_S

No. of false-negative SPECT

varies

Equation 1a

[19–21]

P

Prevalence of CAD

varies

0.1-1.0

[19–21]

ΔQALY’

QALY extended by CAD therapy*

3.0

2.0-4.0

[20]

ΔQALY

Net QALY gained

varies

Equations 1c,2c

[20]